-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Aclaris Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q1 2021 to Q2 2025.
- Aclaris Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2025 was 123M shares, a 71.9% increase year-over-year.
- Aclaris Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 77.3M shares, a 10.7% increase from 2023.
- Aclaris Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 69.8M shares, a 7.05% increase from 2022.
- Aclaris Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 65.2M shares, a 15% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)